🚀 VC round data is live in beta, check it out!
Curis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Curis and similar public comparables like SoftOx Solutions, Active Biotech, Jupiter Neurosciences, NextCell Pharma and more.
Curis Overview
About Curis
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Founded
2000
HQ
Employees
34
Website
Sectors
Financials (LTM)
EV
$8M
Curis Financials
Curis reported last 12-month revenue of $12M and negative EBITDA of ($36M).
In the same LTM period, Curis generated $12M in gross profit, ($36M) in EBITDA losses, and had net loss of ($35M).
Revenue (LTM)
Curis P&L
In the most recent fiscal year, Curis reported revenue of $11M and EBITDA of ($43M).
Curis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12M | XXX | $11M | XXX | XXX | XXX |
| Gross Profit | $12M | XXX | $11M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | ($36M) | XXX | ($43M) | XXX | XXX | XXX |
| EBITDA Margin | (304%) | XXX | (390%) | XXX | XXX | XXX |
| EBIT Margin | (285%) | XXX | (408%) | XXX | XXX | XXX |
| Net Profit | ($35M) | XXX | ($43M) | XXX | XXX | XXX |
| Net Margin | (297%) | XXX | (398%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Curis Stock Performance
Curis has current market cap of $15M, and enterprise value of $8M.
Market Cap Evolution
Curis' stock price is $1.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $15M | 0.0% | XXX | XXX | XXX | $-3.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCuris Valuation Multiples
Curis trades at 0.7x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Curis Financial Valuation Multiples
As of March 15, 2026, Curis has market cap of $15M and EV of $8M.
Equity research analysts estimate Curis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curis has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15M | XXX | $15M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Curis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Curis Margins & Growth Rates
Curis' revenue in the last 12 month grew by 21%.
Curis' revenue per employee in the last FY averaged $0.3M.
Curis' rule of 40 is (283%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Curis' rule of X is (251%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Curis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | (304%) | XXX | (390%) | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | (19%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (283%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (251%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 130% | XXX | 154% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 256% | XXX | 354% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 507% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Curis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SoftOx Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Active Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Jupiter Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCell Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Poxel | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curis M&A Activity
Curis acquired XXX companies to date.
Last acquisition by Curis was on XXXXXXXX, XXXXX. Curis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Curis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCuris Investment Activity
Curis invested in XXX companies to date.
Curis made its latest investment on XXXXXXXX, XXXXX. Curis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Curis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Curis
| When was Curis founded? | Curis was founded in 2000. |
| Where is Curis headquartered? | Curis is headquartered in United States. |
| How many employees does Curis have? | As of today, Curis has over 34 employees. |
| Who is the CEO of Curis? | Curis' CEO is James E. Dentzer. |
| Is Curis publicly listed? | Yes, Curis is a public company listed on Nasdaq. |
| What is the stock symbol of Curis? | Curis trades under CRIS ticker. |
| When did Curis go public? | Curis went public in 2000. |
| Who are competitors of Curis? | Curis main competitors are SoftOx Solutions, Active Biotech, Jupiter Neurosciences, NextCell Pharma. |
| What is the current market cap of Curis? | Curis' current market cap is $15M. |
| What is the current revenue of Curis? | Curis' last 12 months revenue is $12M. |
| What is the current revenue growth of Curis? | Curis revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Curis? | Current revenue multiple of Curis is 0.7x. |
| Is Curis profitable? | No, Curis is not profitable. |
| What is the current EBITDA of Curis? | Curis has negative EBITDA and is not profitable. |
| What is Curis' EBITDA margin? | Curis' last 12 months EBITDA margin is (304%). |
| What is the current EV/EBITDA multiple of Curis? | Current EBITDA multiple of Curis is (0.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.